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During the late summer of 1998, veterinary authorities in Tuscany, Italy, received reports of cases of neuro-
logic disease among horses residing in a large wetland area located in the provinces of Florence and Pis-
toia. West Nile virus was isolated from two of the six horses that died or were euthanized. A retrospective
epidemiologic study identified 14 clinical neurologic cases that occurred from August 20 to October 6
(attack rate of 2.8%). A serologic survey conducted over a 700-km2 area in stables with and without appar-
ent clinical cases confirmed a wider spread of the infection, with an overall seroprevalence rate of 38% in
the affected area. No significant differences in age-specific prevalence were observed, suggesting that the
horses residing in the area had not been exposed previously to West Nile virus and supporting the hypoth-
esis of its introduction in the wetland area during the first half of 1998.
est Nile virus (WNV), named after the district of Uganda
where the virus was first isolated in 1937 (1), is a mos-
quito-borne Flavivirus belonging to the Japanese encephalitis
antigenic complex in the family Flaviviridae (2). WNV has
been described in Africa, Europe, Middle East, Asia, Oceania
(subtype Kunjin), and, more recently, in North America (3). 
The ecologic aspects of WNV infection, involving mosqui-
toes, birds, and humans, were first described in the 1950s in
Egypt (4). The agent circulates in nature through continuous
enzootic transmission cycles between Culicinae mosquitoes
and avian vertebrate hosts and may be introduced into a new
territory by migratory birds. Humans and horses are consid-
ered incidental hosts. However, an urban cycle with virus
amplification by continuous transmission between birds and
vectors, and incidentally, humans, has been recently described
in Romania and in the United States (5–7). 
The infection in humans is usually asymptomatic; how-
ever, in 20% of cases, an acute, influenza-like, self-limiting
febrile illness may occur, with symptoms of severe encephali-
tis in <1% of the cases (8). Neurologic disease in both humans
and horses was reported for the first time in the late 1950s (9)
and 1960s (10,11) respectively, in the Mediterranean area. In
the past decade, outbreaks in humans have been reported in
Algeria in 1994 (12), in Romania in 1996 and in 1997–1998
(4,13), in the Czech Republic in 1997 (14), in Tunisia in 1997
(H. Triki, pers. comm.), in Russia in 1999 (15), and in birds,
humans, and horses in Israel in 2000 (16). In the summer of
1999, the first recorded appearance of WNV in the Western
Hemisphere caused fatal disease in humans, horses, and birds
in the northeastern United States (5,6,17–19). Outbreaks in
horses were described in Morocco from August to mid-Octo-
ber 1996 (20) with 94 cases and 42 deaths, and in France from
August to November 2000 (21) with 58 confirmed cases and
20 deaths. 
During the late summer in 1998, veterinary practitioners in
Italy recorded an increasing number of cases of neurologic dis-
ease in horses around an 18,000-km2 wetland area located in
the provinces of Florence and Pistoia, known as the Padule del
Fucecchio. The area, which covers the central and southern
part of the Valdinievole Valley, is home to a number of resident
and migratory avian species and is on the route between Afri-
can wintering areas and European breeding sites of waterfowl,
herons, and waders, some of which breed there during the
summer. 
On the basis of preliminary investigation by public health
veterinarians, an outbreak of WNV disease in horses was sus-
pected.  On October 19, 1998, the Regional Veterinary Author-
ity banned the movement of Equidae in and out of a 700-km2
area including 20 municipalities. Preliminary epidemiologic
and laboratory studies implicated WNV as the etiologic agent,
and the ban was lifted 1 month later on November 20, 1998.
By this point, the temperature in the area had dropped below
levels at which Culicinae mosquito multiplication can occur,
and no further cases had been reported since early October.
The objectives of our study were to assess whether an epi-
zootic was occurring among horses residing in the area and to
perform a cross-sectional serosurvey to gather information
about the extension of virus circulation around the wetland
area, once as the cause of the infection was ascertained.
Methods
Retrospective Study 
At the end of September 1998, following the initial occur-
rence of neurologic cases of unknown origin in horses, we ini-
tiated a retrospective study to assess possible common
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exposures. A questionnaire was prepared and distributed to
public health veterinarians and veterinary practitioners, who
were asked to complete it if they had seen or treated horses
during the summer that matched the following case definition:
“clinical signs involving the central or peripheral nervous sys-
tem.” This definition, although broad in scope, was intention-
ally used to include all possible cases in the course of the
investigation. We collected information about location and
size of the stable in which the case had occurred; the number,
sex, age, and breed of horses present; a checklist of neurologic
signs; and the date of onset, duration, and outcome of the clin-
ical course. Additional information requested included
whether the horse had received medical treatment within the
15 days preceding the clinical onset and whether any horse had
been moved into or out of the stable within 30 days of the date
of onset of clinical signs.
During the retrospective study, blood samples were col-
lected in October from 159 horses in the stables where clinical
cases had occurred. At an interval of 30 days, a second round
of sampling was performed on 124 horses from the same sta-
bles. Repeat titers were obtained, from 123 (78%) of the 159
animals bled in October. Further blood samples (n=161) were
collected in 16 stables in proximity with those with clinical
cases. A confirmed case was defined as a horse with neuro-
logic signs suspect of WNV origin, together with at least one
of the following: isolation of WNV, a positive polymerase
chain reaction (PCR) assay, and a positive complement fixa-
tion (CF) test. A complete necropsy was done on all horses
that died during the study, and representative samples of major
organs and of the central nervous system were fixed in 10%
neutral buffered formalin and processed routinely for histopa-
thology. 
Virology, Pathology and Serology
Representative portions of the brain and the entire spinal
cord were submitted for virologic investigations. Part of the
samples were frozen and sent for additional investigations to
the Italian National Center for Exotic Diseases (Istituto
Zooprofilattico Sperimentale Abruzzo e Molise, Teramo,
Italy), the French National Reference Center for Arboviruses
and Viral Haemorrhagic Fevers of the Pasteur Institute (Paris,
France), and the International Reference Center for Borna Dis-
ease (Giessen University, Germany). 
Two horses with neurologic signs were euthanized. A sam-
ple of cerebrum from one animal (no. 4083V) was analyzed in
cell culture and by reverse transcriptase (RT)-PCR and semi-
nested PCR. Samples of the cerebellum and the cervical, tho-
rax, lumbar, and sacrum regions of the spinal cord from the
second animal (no. 4553V) were also tested. The equivalent of
about 0.5 mL of each tissue was mechanically crushed (Mini-
beadbeater, Biospec Products, Inc., Bartlesville, OK) two
times for 30 sec in 2 mL tubes containing 0.5 mL of sterile
glass beads and 0.5 mL of Dulbecco’s minimum essential
medium (DMEM), supplemented with 10% fetal calf serum
(FCS) and antibiotics, and centrifuged at 4,000 rpm for 15
min. The supernatant was diluted 1/10 and 1/100 in the
medium and 0.2 mL of the three undiluted and diluted suspen-
sions were incubated 1 hr at 37°C or 28°C in 24-well plates
containing Vero E6 cells or Aedes albopictus C6/36 cells.
After viral adsorption, cells were washed twice in DMEM and
incubated 5 days in DMEM containing 3% FCS. On day 5, cell
supernatants were used to infect cell monolayers in 25-cm2
flasks and incubated for 5 additional days. Cells in each well
and in the flasks were washed in phosphate-buffered saline
(PBS), scraped with a rubber policeman, and deposited on
immunofluorescent slides. The cells were fixed by air-drying,
the membranes permeabilized in acetone, and dried. The cells
were incubated for 30 min at 37°C with an appropriate dilution
of hyperimmune mouse ascitic fluids prepared against several
arboviruses causing encephalitis in horses. After washing in
PBS, the bound antibodies were overlaid with an anti-mouse
conjugate labeled with fluorescein. Slides were observed
under fluorescent microscope. 
RT-PCR and semi-nested PCR were performed on central
nervous system samples, using a technique described previ-
ously (22). Briefly, total RNA was extracted from a volume of
supernatant of ground central nervous system samples. Precipi-
tated RNA was resuspended in diethyl pyrocarbonate–treated
distilled water and subjected to RT and PCR, using the oligonu-
cleotide primers (23) WN240 (5´ GAGGTTCTTCAAACTC-
CAT 3´) and WN312 (5´ GAAAACATCAAGTATGAGG 3´).
One tenth of the incubation mixture was then re-amplified
in a semi-nested PCR, using primers WN312 and WNEsn, (5´
CTCCA(T,G)GG(G,C)AGGTT(G,C)AG(G,A)TCCAT 3´). The
presence of amplicons of 328 bp and 270 bp, respectively,
were examined after 1.5% agarose gel electrophoresis and
ethidium bromide staining. The sequences of the amplified
products were characterized by sequencing genome position
1402-1656 of the envelope glycoprotein as described (23) by
using the alignment algorithm Clustal W.
Serum samples from 12 of the 14 diseased horses were
available; the remaining 2 horses had died without having
blood samples taken. Additional samples were also available
from the same premises where clinical cases had occurred and
from nearby stables collected as part of the serologic survey
described in the following section. Serum samples were first
tested against the major neurotropic viruses infecting horses,
including Eastern equine encephalomyelitis, Western equine
encephalomyelitis, and Venezuelan equine encephalomyelitis.
The presence of antibodies against WNV was evaluated using
the CF test and by an immunoglobulin (Ig)G enzyme-linked
immunosorbent assay (ELISA) technique. 
Reagents for the CF test were supplied by the Onderste-
poort Veterinary Institute, South Africa, and the Centers for
Disease Control and Prevention, Division of Vector-Borne
Infectious Diseases, Fort Collins, Colorado. The CF test
assays were performed by the Italian National Center for
Exotic Diseases according to the Office International des Epi-
zooties procedures (24). The CF test was considered positive
when the sample reacted at a titer of  >1:4. RESEARCH
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Crude antigens for ELISA were prepared from Vero E6
cells infected with the reference Egyptian Eg101 as described
(25). Microtiter plates (Polysorb, Dynatech, Chantilly, VA)
were alternately coated with 100 µL of WNV cell lysate anti-
gen and with antigen derived from uninfected Vero cells.
Plates were kept overnight at 4°C. Fourfold dilutions of horse
sera, starting with 1:100, were placed in the wells. Bound IgG
antibody was detected with goat anti-horse IgG conjugated to
horseradish peroxidase. H2O2-tetramethylbenzidine was
added and the optical density was measured at 420 nm. Serum
samples were considered positive for corrected A420 values
greater than the corrected mean A420 plus 3 standard devia-
tions of four negative control sera tested at the same dilution. 
Serologic Survey
After the initial notification of neurologic cases in horses,
an area consisting of several administrative jurisdictions from
which cases had been reported was delineated, and movement
of horses in and out of the area was banned. The cause of the
illness was not available at that time, and initial clinical and
serologic investigations focused on stables located within a 3-
km radius of those that had reported clinical cases.
By November 1998, when WNV was identified as the etio-
logic agent, we initiated a serosurvey to further define the geo-
graphic extent of the infection. The most peripheral stables
within the restricted zone were used as reference points to con-
struct a polygonal area whose external angles were all <180°
(zone A). As shown in Figure 1, a second polygon was then
drawn around the first, with all points 3 km distant from the
internal polygon. Thus, a 3-km wide corridor between the first
and second polygons was identified (zone B), all stables in this
area were investigated, and blood samples from all horses
were obtained. After identification of at least one seropositive
horse in a stable located within the corridor, the polygon was
redrawn with the new positive stable becoming a vertex of a
new polygon and the corridor extended an additional 3 km
(zone C). A total of 282 horse serologic data (IgG ELISA)
were collected. Data were analyzed with the BMDP program
version 1.0 (BMDP Statistical Software, Inc., Los Angeles,
CA)
Results
Pathology
No gross changes were observed in the central nervous
system and other organs of the six dead horses. Histologically,
a mild-to-moderate nonsuppurative polioencephalomyelitis
was present, with consistent involvement of the ventral horns
of the thoracic and lumbar spinal cord and of the lower brain
stem. Perivascular cuffs of lymphoplasmacytic and histiocytic
cells with small and scattered glial nodules and focal gliosis
were observed in the gray matter. In some cases, ring and pete-
chial hemorrhages and neuronal degeneration were observed
in the lumbar spinal cord (26). These features were highly sug-
gestive of an infection of viral origin.
Virology
WNV was recovered in the cerebellum (Vero E6 and C6/
36) (virus isolate PaAn981) and lumbar part (Vero E6) of the
spinal cord of horse no. 4553V. RT-PCR was positive with
samples from the cerebellum and the thorax and lumbar
regions of the spinal cord. WNV was not isolated from the
cerebrum of horse no. 4083V; however, RT-PCR results were
positive. Both virus isolation and RT-PCR results were nega-
tive from the cerebrum of horse no. 4553V. In all cases, RT-
PCR gave a negative result. Laboratory investigations on other
viruses affecting horses yielded a negative result.
The sequence of the amplified fragment of 255 bp from the
PaAn981 Italian virus RNA (GenBank accession no.
AF205883) showed >99% similarity in nucleotide sequence
with recent WNV strains responsible for epidemics in Roma-
nia in 1996 (GenBank accession no. AF260969), Morocco in
1996 (accession no. AF205884), Kenya in 1998 (accession no.
AF146082), Volgograd in 1999 (accession no. AF239988,
Israel in 2000 (accession no. AF380669), and France in 2000
(accession no. AF418554) and 98.6% similarity with strains
from Israel in 1998 (accession no.  AF205882) and New York
in 1999 (accession no. AF196835). No change was observed
in the amino acid sequence of this short region of the envelope
protein. 
Figure 1. Map of the study area, showing the inner polygon within the
restricted zone (zone A), the corridor area (zone B), and the redrawn
corridor area (zone C), in the provinces of Firenze, Lucca, and Pistoia,
Tuscany Region, Italy.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1375
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Retrospective Study
The questionnaires sent to local veterinarians were
returned by the end of October 1998. A total of 14 horses that
matched the case definition were identified. They were distrib-
uted in nine different stables located in the provinces of Flo-
rence, Lucca, Pisa, Pistoia (Figure 1). The first case occurred
on August 20 and the last on October 6. Of the 14 horses, 8
recovered, and 2 died 1 and 3 days, respectively, after onset of
signs. The remaining four were euthanized because of the
severity of the clinical course. The most frequently observed
signs were posterior weakness, ataxia, and loss of equilibrium.
In the eight animals that recovered, signs persisted for 5–15
days. In three cases, additional clinical signs were observed
(mild keratitis, dermal papules, and third eyelid protrusion).
Fever was observed in one case, at onset of disease.
Overall, the attack rate in the nine affected stables was
2.8% (14/498, Table 1). The case-fatality rate among horses
with neurologic signs was 43% (6/14) including the four
horses that were euthanized. No difference in age was detected
between fatal cases (horses that died or were euthanized) and
those that recovered (Mann-Whitney U Test). 
The temporal distribution of equine cases by week of ill-
ness onset is shown in Figure 2.
On the 12 diseased horses for which blood was available
for testing, CF test results were positive for all, with titers
ranging from 1:4 to 1:128. In the nine stables from which clin-
ical cases had been notified, 159 of the 498 horses present
were bled in October and serologically tested, with 123 of 159
tested a second time 1 month later.
The overall results of the CF test are shown in Table 1.
Table 2 shows the results of the first and second round of sam-
pling in the 123 horses that were tested twice. The seropreva-
lence rate was significantly different between the two
samplings (McNemar chi-square test; p<0.01). The 29 horses
that were positive at first and second sampling had a geometric
mean titer of 1:29 in the first sampling and 1:6 in the second
sampling; this difference was statistically significant (Student t
test for paired sera on log transformed data, p<0.01). Among
the remaining 18 horses that initially tested positive but were
negative at second testing, the geometric mean titer of the first
sample was 1:15.
Serum samples were collected from an additional 161
horses in November 1998 (>3 weeks after the last reported
clinical case) from 16 stables located within a 3-km radius
from the ones with clinical cases in zone A. Samples were
tested first with CF test and later with an IgG ELISA, not
available at the beginning of the epidemic. Of the 161 horses,
63/155 (41%) had positive ELISA tests (6 horses were
excluded because of inconclusive results) and 30/161 (19%)
were CF test–positive with titers ranging from 1:4 to 1:8. The
positive horses belonged to nine different premises. The over-
all seroprevalence rate in these nine stables was 49% (63/129)
when the IgG ELISA test was used and 22% (30/134) with the
CF test (Table 3). 
To investigate whether rates of seropositivity differed
between premises with and without clinical cases, the propor-
tion of horses that were CF test–positive from the stables with
clinical cases was compared with the proportion obtained for
horses from the stables with silent infections. Because CF test
results are likely to be dependent on the time of infection, the
comparison consisted of the November samples from stables
with silent infections and the second set of samples taken from
horses from stables with clinical cases, also obtained in Novem-
ber (all stables from zone A). No significant difference was
observed in rates of infection for the two groups (chi-square test
p>0.05).
In February–April 1999, serum samples were obtained
from all the 123 horses never tested before and housed in 35
stables located in zones B and C. Seroprevalence using the
IgG ELISA test was 43/120 (36%), with three inconclusive
tests. CF test prevalence was 19/123 (15%), with titers ranging
from 1:4 to 1:8. Fourteen stables were found positive in zone
B and none in zone C (Figure 1).
Among the 123 horses tested in zones B and C, informa-
tion on presence in the area during the outbreak period was
Table 1. Complement fixation test findings in stables with clinical 
cases (zone A)a
Stable Horses present Clinical cases
Seroprevalence
1st samplingb 2nd samplingc
1 25 2 11/21 (52.4%) not available
2 5 1 3/5 (60%) 1/3 (33.3%)
3 12 2 6/10 (60%) 6/10 (60%)
4 49 2 9/13 (69.2%) 5/11 (45.4%)
5 7 1 2/7 (28.6%) 1/5 (20%)
6 270 1 5/49 (10.2%) 3/41 (7.3%)
7 52 1 9/20 (45%) 2/20 (10%)
8 18 1 6/8 (75%) 5/9 (55.5%)
9 60 3 12/26 (46.1%) 8/25 (32%)
Total 498 14 63/159 (39.6%) 31/124 (25%)
a Repeat titers (October–November 1998) were obtained from 123 horses.
bPerformed October 12–16, 1998.
cPerformed November 9–13, 1998. 
Figure 2. Number of neurologic cases in horses by week of onset, Valdi-
nievole District, Tuscany, Italy, August–October 1998.RESEARCH
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available for 110, including 107 that had been present and 3
that had not. Of the 107, 40 tested positive (37%); among the 3
not present, 1 was positive. Among the 13 horses whose loca-
tion during the epidemic could not be established, 2 were
seropositive. 
The results of serum samples collected in zones B and C at
the beginning of 1999 before the growth of the vector popula-
tion were compared to the results of sera from the stables with-
out clinical cases (zone A) collected during the autumn 1998.
No differences were found between the percentages of animals
seropositive by ELISA (36% vs. 41%) and CF test (15% vs.
19%). For this reason, to obtain a larger sample, all data were
pooled to assess the age-specific prevalence in the horse popu-
lation under study.
A total of 282 horses were included in the analysis (Table
4) and classified according to age group and serologic status
with respect to IgG ELISA (106 were positive; 9 were at the
A420 cut-off value and inconclusive). No significant differ-
ences (chi-square >0.05) in the seroprevalence rate among the
different age-classes were observed (Figure 3). The results of
this survey confirmed a wider spread of infection, with an over-
all seroprevalence rate of 38% (106/282) in the affected area. 
Discussion
An epidemic of WNV encephalitis occurred during the late
summer of 1998, among horses residing in a wetland area in
the Valdinievole Valley, in the provinces of Florence and Pis-
toia, Tuscany. All the cases identified by the retrospective
study were confirmed by serologic, or virologic assays, or
both.
The outbreak involved race horses and racehorse breeding
stock of high economic value, and the spatial and temporal
nature of this cluster aided the investigation, as did the fact
that local practitioners brought the problem to the attention of
veterinary public health authorities early in the the outbreak.
The serologic survey demonstrated that WNV infection also
occurred in premises without clinical cases and that WNV was
spread over an area wider than initially detected during the
epidemic. 
Although the number of confirmed cases reported is small,
the case-fatality rate of this 1998 Italian outbreak (6/14, 43%)
is similar to the rate observed in 2000 in France (20/58, 34%),
and in 1999 (23/60, 38%) and 2000 (9/25, 36%) in the United
States (21,19). No differences in age were detected between
fatal cases (horses that died or were euthanized) and those that
recovered. Three of six fatal cases were observed in horses <6
years old, with one case 6 months old, one case 2 years old,
and one case 5 years old. In the recent equine outbreak in
France (21), >70% of the fatal cases occurred in horses in the
6- to 10-year (41.2%) and the 16- to 20-year (29.6%) age cate-
gories, with only one confirmed fatal case in the 1- to 5-year
age category (5.9% of the fatal cases). 
In our study, WNV was isolated from different parts of the
central nervous system, and similar results were obtained in a
horse with encephalitis euthanized during the epidemic in
France in 1965 (27). In that case, WNV was isolated in cell
cultures injected with material obtained from the lumbar
region of the spinal cord but not with material from the cervi-
cal region of the spinal cord, the cerebrum, or the cerebellum.
Although based on a very limited number of observations, we
observed that the lower compartments of the brain and the spi-
nal cord may be more infected than the cerebrum when the
neurologic signs are predominant and the animal is dying.
Moreover, the presence of neuronal necrosis in the brain in the
absence of virus and the detection of both inflammatory
lesions and virus in the lower brain stem late in the infection
process suggest that the agent may have migrated from central
brain areas downwards through the spinal cord (26). The low
virus load in the central nervous system is in accordance with
the small number of necrotic areas within the brain and the spi-
nal cord tissues (3,26). 
Two different serologic tests, which detect different classes
of antibodies, can be used to distinguish between recent and
past infections. CF test is used primarily to monitor IgM,
Table 2. Comparison between first sampling (acute, October 1998) and 
second sampling (convalescent, November 1998) complement fixation 
test results in horses from the stables with clinical cases (zone A)
1st sampling
Positive Negative Total
2nd sampling Positive 29 1 30
2nd sampling Negative 18 75 93
Total 47 76 123
Table 3. Enzyme-linked immunosorbent assay (ELISA) and comple-
ment fixation (CF) test results in horses from stables with silent infec-
tion (zone A)
ELISA
Positive Negative Total
CF test Positive 26 4 30
CF test Negative 37 88 125
Total 63 92 155
Table 4. Horses, classified by age class and serologic status (immu-
noglobulin G enzyme-linked immunosorbent assay), included in the 
analysis to assess age-specific prevalencea
Age class (yrs) Horses tested Inconclusive Positive
0–2 45 3 17
2–4 63 1 21
4–6 49 1 18
6–8 30 1 10
>8 95 3 40
Total 282 9 106
a282 horses included because the age of 2 animals was unknown.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1377
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although this test may not detect exclusively this class of anti-
bodies, and the ELISA test is specific for IgG. The decline in
the mean CF test antibody titer over a 1-month period (Octo-
ber–November 1998) in stables with clinical cases seems to be
attributable to the natural decrease of CF antibody levels. The
rapid decline in CF test titers may also explain the lower pro-
portion of CF test–positive horses in the second and third
groups that were tested in November and in early 1999. In the
zone A stables, which had silent infections and that were
investigated in November 1998, the CF test prevalence rates
were similar to the rates detected in the November samples
taken from the neighboring stables with clinical cases. As sim-
ilar IgG ELISA prevalence rates were obtained both in these
stables with silent infections located in zone A and in stables
in zone B (sampled in early 1999), we assume that, apart from
the observation of neurologic signs, all horses residing in the
study area had the same level of exposure to the virus.
Retrospectively, serologic results suggest that the epidemic
ended during the autumn of 1998, probably because further
major circulation of virus was greatly reduced by the effect of
the low temperature on the population density of mosquitoes.
However, at present no information is available regarding the
vector species involved in this outbreak. 
The seasonal distribution we observed is in keeping with
other studies. All previous equine and human outbreaks of
WNV infection in Europe and the Mediterranean area typi-
cally have occurred between August and October (9,21), the
period when the population density of culicine mosquitoes is
highest. Similar observations were made in the United States
in the equine outbreaks in 2000 (19), with cases identified in
seven northeastern states situated at latitudes similar to that of
central and northern Italy. 
The differences among age-specific prevalence rates in the
whole area under investigation were not significant, indicating
that the horse population in the area under study had not been
exposed in the previous years to WNV. The most probable
hypothesis is that the virus was introduced in the Padule del
Fucecchio wetlands by migratory birds during the spring 1998.
Migratory birds such as storks may play an essential role in the
introduction of WNV when they land in wetlands with high
levels of ornithophilic mosquitoes (28). The circulation of a
unique genotype in Italy in 1998, Morocco in 1999, and
France in 2000 suggests that migratory birds crossing the
Mediterranean Sea could be the common cause of virus emer-
gence. The 1998 WNV outbreak in Italy was not preceded by
notification of any significant deaths among wild avian spe-
cies. Indeed, natural illness and death of wild birds resulting
from WNV had never been reported before the 1998 episode
in storks in Israel (28) and the 1999 epidemic in birds reported
in the northeastern United States. Old World wild avian spe-
cies may have developed co-evolutionary adaptation to vari-
ous WNV genotypes; the recent North American epidemic
could have occurred because the lack of avian adaptation or
the greater virulence, especially for Corvidae (29), of the
strain involved. The recent European WNV outbreaks were
apparently not associated with bird deaths (5,21,15). The com-
parison of the amino acid sequence of the entire envelope pro-
tein among European WNV isolates and strains from Israel
1998 and New York 1999, known to be significantly patho-
genic for some species of birds (30), showed two amino acid
changes that are attenuating mutations for other flaviviruses of
the Japanese encephalitis group (31). Whether viral genetic
factors or ecologic factors are responsible for apparent differ-
ences in virulence for birds, horses, and humans remains
unknown and merits further multidisciplinary investigation. 
In 1999 and 2000, no cases of neurologic disease were
recorded in horses in Tuscany, and no significant wild bird
deaths or rise in human neurologic cases were detected. Unfor-
tunately, conducting further studies to determine if any viral
activity was still present in the area was not possible. The risk
that WNV could remain endemic in the area because of transo-
varial transmission or overwinter survival of mosquitoes can-
not be ruled out. However, at least in temperate regions of
Eurasia, the usual pattern of WNV epidemics may be the result
of virus importation by birds during their migration north to
their breeding grounds (32). Still, outbreaks of WNV infection
are a relatively rare event in countries where populations of
wild birds regularly migrate every year from endemic areas.
The reason may be that the emergence of a mosquito-borne
infection always involves a series of particular ecologic condi-
tions, including seasonal environmental factors, presence of
infectious migrating hosts, ornithophilic vectors, amplifying
avian hosts, and susceptible accidental hosts in the same geo-
graphic area.
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